Clinical Trial News and Research

RSS

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

CPhI reports positive outlook on the Chinese pharmaceutical market

CPhI – a division of UBM EMEA – alongside UBM Sinexpo, announces the findings of the Pharma Insights China 2015 report.

13 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.

13 Aug 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015

RSAM, Rettsyndrome.org renew commitment to jointly defeat Rett syndrome

The Rett Syndrome Association of Massachusetts and Rettsyndrome.org announce today their renewed commitment to work together to defeat Rett syndrome. A generous $85,000 donation from RSAM will support an ongoing clinical trial for Rettsyndrome.org at Boston Children's Hospital.

13 Aug 2015

Newly developed big data technique may have significant impact on health care

Rice University scientists have developed a big data technique that could have a significant impact on health care. The Rice lab of bioengineer Amina Qutub designed an algorithm called "progeny clustering" that is being used in a hospital study to identify which treatments should be given to children with leukemia.

13 Aug 2015

First clinical trial to test use of retinal progenitor cells for treating retinitis pigmentosa begins

Participants are being enrolled in the first clinical trial that tests the use of retinal progenitor cells to treat retinitis pigmentosa, reported project director Dr. Henry Klassen of UCI's Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center. The product of stem cell research at UCI, these retinal progenitors are similar to stem cells in terms of potential regenerative properties, but they're specific to the retina.

13 Aug 2015

IASLC announces winners of Advocacy Travel Awards

The International Association for the Study of Lung Cancer announced today the recipients of the Advocacy Travel Awards. Five winners will receive funding to attend the 16th World Conference on Lung Cancer (WCLC) Sept. 6-9, 2015 at the Colorado Convention Center in Denver.

13 Aug 2015

Chances of survival due to chemotherapy significantly lower for older breast cancer patients

Chemotherapy prolongs life for older adults with most types of cancer, but for women over the age of 80 with breast cancer, the chances of survival due to chemotherapy are significantly lower, according to a study led by researchers from The University of Texas Health Science Center at Houston.

13 Aug 2015

Echo's non-invasive CGM system to be designated as Class 2 medical device in China

Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.

12 Aug 2015

$AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion$

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

12 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.

12 Aug 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC.

11 Aug 2015

Marken signs agreement with OnAsset for use of advanced GPS tracking device on drug shipments

Marken, the leading clinical logistics organization (CLO), has entered into an exclusive agreement with OnAsset Intelligence Inc. for use of their most advanced GPS tracking device on key shipments. The device will significantly improve Marken's real-time, track and trace capability through custom-designed software.

11 Aug 2015

Statisticians create new technique that helps doctors to optimize dose of cancer treatments

A new technique developed by statisticians that is helping doctors optimize the dose of a new cancer treatment patients receive in phase I/ II clinical trials was presented today by Juhee Lee, assistant professor of applied mathematics and statistics at the University of California, Santa Cruz, during a session at the 2015 Joint Statistical Meetings (JSM 2015) in Seattle.

11 Aug 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

A Veterans Affairs database study of more than 83,000 patients found that men whose low testosterone was restored to normal through gels, patches, or injections had a lower risk of heart attack, stroke, or death from any cause, versus similar men who were not treated.

11 Aug 2015

Clinical Trial News and Research

Rhythm Metabolic completes $40 million Series A financing

CPhI reports positive outlook on the Chinese pharmaceutical market

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

Dipexium reports net loss of $4.0 million for second quarter 2015

ESC Congress to highlight results from global trials in six press conferences

RSAM, Rettsyndrome.org renew commitment to jointly defeat Rett syndrome

Newly developed big data technique may have significant impact on health care

First clinical trial to test use of retinal progenitor cells for treating retinitis pigmentosa begins

IASLC announces winners of Advocacy Travel Awards

Chances of survival due to chemotherapy significantly lower for older breast cancer patients

Echo's non-invasive CGM system to be designated as Class 2 medical device in China

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

Ardelyx reports net income of $9.0 million for second quarter 2015

Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Marken signs agreement with OnAsset for use of advanced GPS tracking device on drug shipments

Statisticians create new technique that helps doctors to optimize dose of cancer treatments

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer